66 results
To increase the fraction of patients with a PET-negative metabolic complete remission after second line chemotherapy with 3 courses of DHAP , each in combination with one i.v infusion of BV. This will make more patients eligible for high dose…
Primary: To compare progression-free survival (PFS) between erlotinib alone and cisplatin-pemetrexed-erlotinib in patients with EGFR mutated NSCLC locally advanced and metastatic disease stage IIIB and IV.Secondary: To characterize toxicities of…
There are two primary objectives in this study: The first of them is to evaluate in a blinded randomized trial, whether the hypoxic cell radiosensitizer nimorazole can improve the effect of primary curative accelerated fractionated concomitant chemo…
Phase I study to investigate safety of the combination indomethacin and two platinum-based chemotherapy regimens in patients with advanced cancers.
The most important questions of this phase III trial is:Can adaptive high dose radiotherapy improve loco-regional control without increase of toxicity?
Primary: To compare Event-free survival (EFS) per RECIST in subjects treated with pembrolizumab in combination with CRT and subjects treated with placebo in combination with CRT.Secondary:(1) To compare Overall Survival (OS) in subjects treated with…
This study is designed to assess the efficacy and safety of pembrolizumab monotherapy compared with SoC platinum doublet chemotherapy for first-line treatment of participants with dMMR advanced or recurrent EC. The primary objectives are to compare…
Primary objective:-To assess the efficacy of durvalumab plus olaparib combination therapy compared with durvalumab monotherapy in terms of PFS (Investigator-assessed)Secondary objectives:- To further assess the efficacy of durvalumab plus olaparib…
Primary ObjectivesEvaluate the efficacy of pemigatinib versus gemcitabine plus cisplatin in the first-line treatment of participants with cholangiocarcinoma with FGFR2 rearrangement. Secundary ObjectivesEvaluate the efficacy of pemigatinib versus…
This Phase III study, the administration of durvalumab + chemotherapy prior to surgery, followed by administration of durvalumab after surgery, will be investigated in patients with resectable Stages II and III NSCLC. The efficacy of durvalumab will…
Primary end point• Progression-free survival (PFS) per ICR central assessmentSecondary end point• Objective response rate (ORR)• Disease control rate (DCR)• Overall survival (OS)• PFS according to Investigator assessment of radiologic images•…
The research hypothesis for this study is that concurrent durvalumab plus SoC chemotherapy will be more effective than placebo plus SoC chemotherapy for the treatment of MRD+ patients who have undergone complete resection of stage II-III NSCLC when…
The hypothesis is that personalised and risk-adapted treatment will improve outcome and reduce toxicity in post-pubertal patients with medulloblastoma.A further hypothesis is that clinical, magnetic resonance imaging (MRI) and voxel-based…
The purpose of this study is to evaluate the safety, pharmacokinetics, and activity of GDC-6036 combined with other anti-cancer therapies in patients with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC) that harbors a…
Primary objective:- Investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis (>2mm) and/or extracapsular extension in the sentinel lymph nodeSecondary…
PRIMARY OBJECTIVES*Rx-induction: Comparison of the 3 year EFS rate of 2 induction regimens, GPOH and RAPID COJEC, in patients with high-risk neuroblastoma.*Rx-HDC: Comparison of the 3 year EFS rate from randomization of single HDC with Bu-Mel versus…
To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.
The primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin compared with standard of care (adjuvant capecitabine) in patients with BTC after complete resection in terms of DFS.Secondary objectives are safety and…
The two main objectives of the study are:* To assess the efficacy of ADT in treatment naïve patients with recurrent and/or metastatic, androgen receptor (AR) expressing, SGCs. The primary measure of efficacy is Progression-Free Survival (PFS).* To…
To determine the activity and safety of nivolumab (as monotherapy or in combination with other immunomodulatory treatments) after different immune response induction treatments in TNBC patients with metastatic disease.